Detalhe da pesquisa
1.
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
EClinicalMedicine
; 63: 102160, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649806
2.
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Lancet Reg Health Am
; 21: 100497, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37192953
3.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
EClinicalMedicine
; 46: 101383, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35434578